ClinicalTrials.gg
RecruitingNCT06096909Updated Oct 27, 2026

Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population

A Phase 4 interventional study of Tafolecimab and Cholesterol Absorption Inhibitor in Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome and Lipid Lowering, Vascular Inflammation, sponsored by China National Center for Cardiovascular Diseases. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by China National Center for Cardiovascular Diseases · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.
Updated Oct 27, 2026Now RecruitingFirst site in China+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3,684
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Acute Coronary Syndrome with a site in China — 55 open to participants now, 63 under way, 3 of them phase 3. Acute Coronary Syndrome · China.

Planned enrollment
20th of 115
3,684 · median 499
Started
2023
with 12 others
Phase 4
47 of 185
12 open now
Primary completion
2028-03
later than 53 of 62 live
Registered
135th of 185
by date
Lead sponsor
6 of 185
China National Center for Cardiovascular Diseases

Among the 185 studies in Acute Coronary Syndrome with a site in China, this one is the 20th largest by planned enrollment of the 115 interventional ones that give a count, is one of 13 that started in 2023, is one of 47 in phase 4, reaches primary completion later than 53 of the 62 other live ones, and was the 135th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

55 of the 185 studies in Acute Coronary Syndrome with a site in China are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Acute Coronary Syndrome with a site in China, or all of them as a file.
02

Study summary

For patients with ACS undergoing PCI, intensive lipid-lowering including PCSK9 monoclonal antibody should be started as soon as possible, that is, lower LDL-C level should be achieved as soon as possible. Compared with conventional lipid-lowering regimen, it is expected that the occurrence of major adverse cardiovascular events can still be reduced after drug discontinuation. Therefore, the optimization strategy of "for patients with ACS undergoing PCI, intensive lipid-lowering with PCSK9 monoclonal antibody can be started as soon as possible" is proposed.

Read the detailed description

Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide, and its incidence is increasing yearly in China, which has not yet reached the inflection point. Acute coronary syndrome (ACS) is a severe form of ASCVD, and lipid-lowering and antithrombotic therapy are the two core therapies. In the latest ESC/EAS guidelines for lipid management, for ACS patients, the target LDL-C is \<1.4 mmol/L and ≥50% reduction from baseline, and specific initiatives to achieve this target are proposed, emphasizing the timing of clinical application and status of the novel lipid-lowering agent-proprotein convertase subtilisin/kexin type 9 monoclonal antibody (PCSK9) (hereafter referred to as PCSK9 antibody). In recent years, large-scale randomized controlled trials and outcomes of PCSK9 antibodies have demonstrated that PCSK9 antibodies further reduce adverse cardiovascular events by significantly lowering LDL-C levels under the background statin (±cholesterol absorption inhibitor ) therapy. The introduction of PCSK9 antibodies allowed for the reduction of LDL-C to unprecedented levels. From the "cholesterol principle" perspective, it is theoretically reasonable to add a PCSK9 inhibitor to statins as soon as possible during hospitalization for ACS patients. Still, there is no clear evidence from large RCTs. Current evidence supports that for ACS patients, PCSK9 antibodies could be used only when LDL-C is still not up to standard based on treatment with the maximum tolerable dose of statins during the first 2-3 months. However, the immediate initiation of PCSK9 antibodies during the acute phase of ACS (before hospital discharge) has yet to be studied.

03

Conditions studied

  • Acute Coronary Syndrome
  • Non ST Segment Elevation Acute Coronary Syndrome
  • Lipid Lowering, Vascular Inflammation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 75 years;
  • clinical diagnosis with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) ;
  • undergoing PCI
  • baseline LDL-C 1.8 mmol/L 3.4 mmol/L note: NSTE-ACS includes non-ST-elevation myocardial infarction and unstable angina.

Exclusion criteria

Exclusion Criteria:

  • Severe heart failure (Killip III or IV) or cardiogenic shock;
  • Previous hemorrhagic cerebrovascular disease history;
  • Uncontrolled or recurrent arrhythmic events;
  • poorly controlled hypertension;
  • Severe hepatic and renal insufficiency (/AST> 3 times , \<30 ml/kg/1.73m2, or ongoing dialysis) or creatine kinase elevation>5 times upper limit of normal
  • malignant tumor;
  • Intolerance to statins or cholesterol absorption inhibitors;
  • Intolerance to injections;
  • \<1 year;
  • poor compliance.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
3,684 participants (estimated)

Study arms

  • Experimental
    Tafolecimab group

    Intensive LLT with tafolecimab (150 mg every 2 weeks) add to statin ± cholesterol absorption inhibitor. The intervention of this trial is divided to two different stages to stimulate the comparison of "SESS" or "step by step" lipid lowering strategy, including 1) conventional LLT (statin ± cholesterol absorption inhibitor) with tafolecimab (150 mg every two weeks) or not till the end of 24 weeks, and 2) physician decisions according to the local guideline of cholesterol management (\< 1.8 mmol/L) in both groups from the start of 25th week till the end of 104 weeks. The statin refers to the maximal tolerated dose of statins every day. The cholesterol absorption inhibitors includes ezetimibe 10 mg and hybutimibe 10 mg every day. The statin or cholesterol absorption inhibitors use before enrollment will not be inhibited, while any injection of PCSK9 inhibitors within six months before enrollment will not be allowed. Other non-LDL-C lowering drugs can be also used and recorded in detail.

    Drug: Tafolecimab · Drug: Statin

  • Active comparator
    control group

    Conventional lipid lowering therapy with statin ± cholesterol absorption inhibitor.The statin refers to the maximal tolerated dose of statins every day. The cholesterol absorption inhibitors includes ezetimibe 10 mg and hybutimibe 10 mg every day. The statin or cholesterol absorption inhibitors use before enrollment will not be inhibited, while any injection of PCSK9 inhibitors within six months before enrollment will not be allowed. Other non-LDL-C lowering drugs can be also used and recorded in detail. After enrollment, a recommended statin and cholesterol absorption inhibitors using guideline to adjust LLT will be sent to each physicians to calculate how to make each patients achieve the LDL-C target. Adjustments will be permitted within 24 weeks only under predefined conditions: 1) the occurrence of serious LLT-related side effects, or 2) for patients in the control group, if their LDL-C levels are inadequately controlled via protocol-specified criteria at Visit 1 (Week 4).

    Drug: Cholesterol Absorption Inhibitor · Drug: Statin

Interventions

  • The PCSK9 mAb in this study is defined as Tafolecimab 150mg q2w subcutaneously. For the two groups of lipid-lowering regimens, the lipid-lowering drug regimens other than PCSK9 mAb were maintained throughout the study as much as possible in accordance with the guidelines related to blood lipids, provided that no serious safety problems occurred.

  • DrugCholesterol Absorption Inhibitor

    Cholesterol absorption inhibitors (like Ezetimibe and Hybutimibe) are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Ezetimibe 10mg Po qd.

  • DrugStatinsStudies of StatinsStatins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Statin are based on physician decisions, but need to be routinely dosed. Examples of Medications that Meet Study Requirements: Atorvastatin 20mg Po qn, Rosuvastatin 10mg Po qn or Pitavastatin 4mg Po qn.

06

What researchers measure

Primary outcomes

  1. Major adverse cardiovascular and cerebrovascular events (MACCE)

    The primary endpoint of this trial is major adverse cardiovascular and cerebrovascular events at visit 4 (week 104), defined as the composite endpoints of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina and coronary revascularization. Coronary revascularization included PCI or coronary artery bypass grafting (CABG). The coronary revascularization will be conducted based on the presence of ischemia. To evaluate the ischemic need for coronary revascularization, specific assessments will be utilized. Laboratory examinations will include blood tests to check for markers of myocardial injury, such as troponins. Electrocardiograms will be assessed. Unstable angina is defined as typical angina symptoms that have worsened in the past month, with a single episode lasting more than half a minute and that do not resolve spontaneously. The definition of MI is referenced from the fourth Universal Definition of Myocardial Infarction (UDMI)

    Time frame: week 104

Secondary outcomes

  1. major adverse cardiovascular and cerebrovascular events

    The key secondary endpoint is the incidence of MACCE at week 26 (Visit 2), defined as a composite of cardiovascular death, nonfatal MI, nonfatal stroke, hospitalization for unstable angina, and coronary revascularization.

    Time frame: week 26

  2. A composite of primary outcome or all-cause death

    Including all-cause death, cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization for unstable angina, and coronary revascularization). The coronary revascularization includes coronary intervention (PCI), coronary artery bypass grafting (CABG).

    Time frame: Week 104

  3. Lipid control outcome

    Lipid control outcome is the proportion of patients achieving an LDL-C reduction of ≥50% from baseline and attaining an LDL-C level of \<1.4 mmol/L.

    Time frame: week 104

Other outcomes

  1. Additional observed endpoint 1

    Cardiovascular death

    Time frame: at the end of 2 years

  2. Additional observed endpoint 2

    non-fatal myocardial infarction

    Time frame: at the end of 2 years

  3. Additional observed endpoint 3

    non-fatal stroke

    Time frame: at the end of 2 years

  4. Additional observed endpoint 4

    hospitalization for unstable angina

    Time frame: at the end of 2 years

  5. Additional observed endpoint 5

    coronary revascularization

    Time frame: at the end of 2 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Mar 2028, 51 months after the start.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 51 months is above that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Nov 2025 → Mar 2028 and completion Nov 2027 → Jun 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 28, 2023
First posted
Oct 24, 2023
StartActual
Nov 11, 2023
Primary completionEst.
Mar 1, 2028was Nov 2025
CompletionEst.
Jun 1, 2028was Nov 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 27, 2026
Sites
2 sites added — first site in China
Show 2 added (2 China)
  • Fuwai Hospital · Beijing, China
  • Tangshan Central Hospital · Tangshan, China
Oct 27, 2026
Start date
Nov 1, 2023→Nov 11, 2023 (actual)
Oct 27, 2026
Primary completion
Nov 1, 2025→Mar 1, 2028
Oct 27, 2026
Study completion
Nov 1, 2027→Jun 1, 2028
Oct 27, 2026
Interventions
Arm changed experimental group→Tafolecimab group
Oct 27, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameMajor adverse cardiovascular and cerebrovascular events (MACCE)at the end of 2 years → week 104
  • DescriptionMajor adverse cardiovascular and cerebrovascular events (MACCE): how it is measured was reworded
Oct 27, 2026
Secondary outcomes
1 edited, 2 added, 1 removed
What changed in the outcomes
  • Editedmajor adverse cardiovascular and cerebrovascular events (MACEs)Time frame: at the end of 6 months → week 26
  • AddedA composite of primary outcome or all-cause deathTime frame: Week 104
  • AddedLipid control outcomeTime frame: week 104
  • RemovedMajor adverse cardiovascular and cerebrovascular events (MACCE)Time frame: at the end of 1 years
Oct 27, 2026
Design
Not applicable→Phase 4
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Not yet recruiting→Recruiting
    2 sites added — first site in China
    Show 2 added (2 China)
    • Fuwai Hospital · Beijing, China
    • Tangshan Central Hospital · Tangshan, China
    Start date Nov 1, 2023→Nov 11, 2023 (now actual)
    Primary completion Nov 1, 2025→Mar 1, 2028
    Study completion Nov 1, 2027→Jun 1, 2028
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameMajor adverse cardiovascular and cerebrovascular events (MACCE)at the end of 2 years → week 104
    • DescriptionMajor adverse cardiovascular and cerebrovascular events (MACCE): how it is measured was reworded
    Secondary outcomes 1 edited, 2 added, 1 removed
    What changed in the outcomes
    • Editedmajor adverse cardiovascular and cerebrovascular events (MACEs)Time frame: at the end of 6 months → week 26
    • AddedA composite of primary outcome or all-cause deathTime frame: Week 104
    • AddedLipid control outcomeTime frame: week 104
    • RemovedMajor adverse cardiovascular and cerebrovascular events (MACCE)Time frame: at the end of 1 years
    Interventions Arm changed experimental group→Tafolecimab group
    Design Not applicable→Phase 4
    + 3 other changes: index terms, verification date and conditions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06096909
Collaborators
Innovent Biologics, Inc.
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Nov 11, 2023
Primary completion
Mar 1, 2028 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Na-Qiong Wu, Doctor
Contact
wunaqiong@fuwaihospital.org
86-88398866
Zheng Yin, Doctor
Contact
yinzheng@fuwai.com
86-88398866
Na-Qiong Wu, Doctor
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital
Yong-Jian Wu, Doctor
principal investigator · Chinese Academy of Medical Sciences, Fuwai Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tafolecimab

Start the discussion